Leerink Partners Begins Coverage on Medpace (NASDAQ:MEDP)

Leerink Partners initiated coverage on shares of Medpace (NASDAQ:MEDP - Free Report) in a report issued on Monday, Marketbeat.com reports. The firm issued a market perform rating and a $330.00 price objective on the stock.

Separately, Robert W. Baird boosted their target price on shares of Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a research note on Monday, January 27th. Nine analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Medpace has a consensus rating of "Hold" and a consensus price target of $376.30.

Medpace Stock Down 1.3 %

Shares of MEDP traded down $4.25 during midday trading on Monday, reaching $312.36. 343,137 shares of the stock were exchanged, compared to its average volume of 298,736. The stock's 50 day simple moving average is $335.90 and its 200 day simple moving average is $339.07. The company has a market cap of $9.52 billion, a P/E ratio of 24.73, a PEG ratio of 3.81 and a beta of 1.47. Medpace has a twelve month low of $302.01 and a twelve month high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping analysts' consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, analysts predict that Medpace will post 12.29 earnings per share for the current year.

Remove Ads

Institutional Investors Weigh In On Medpace

A number of institutional investors have recently modified their holdings of MEDP. Pallas Capital Advisors LLC raised its stake in shares of Medpace by 179.7% in the fourth quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company's stock worth $1,086,000 after purchasing an additional 2,101 shares during the last quarter. Barclays PLC raised its holdings in shares of Medpace by 71.9% during the third quarter. Barclays PLC now owns 19,781 shares of the company's stock valued at $6,603,000 after purchasing an additional 8,275 shares during the last quarter. Sanctuary Advisors LLC lifted its position in Medpace by 20.5% during the fourth quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company's stock valued at $1,738,000 after purchasing an additional 844 shares during the period. Loomis Sayles & Co. L P boosted its holdings in Medpace by 7.2% in the third quarter. Loomis Sayles & Co. L P now owns 205,798 shares of the company's stock worth $68,696,000 after purchasing an additional 13,880 shares during the last quarter. Finally, Cerity Partners LLC increased its position in shares of Medpace by 18.7% during the 3rd quarter. Cerity Partners LLC now owns 61,890 shares of the company's stock valued at $20,659,000 after purchasing an additional 9,741 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.